Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CalciMedica, Inc. (CALC)

CalciMedica files prospectus supplement for up to $25 million in stock sales

Neutral Impact 2 of 5 financing Written later

CalciMedica filed a prospectus supplement covering the sale of up to $25,000,000 of its common stock through an at-the-market offering agreement with H.C. Wainwright & Co. The filing sets up a possible share sale program but does not state that any shares have been sold or at what price. Because new shares could dilute existing holders, the filing is relevant to shareholders.

Key points

  • Up to $25,000,000 of common stock may be sold under the at-the-market offering agreement dated August 11, 2023
  • Sales are made under shelf registration Form S-3 (No. 333-293972), filed March 3, 2026 and declared effective March 11, 2026
  • Cooley LLP legal opinion on the legality of the shares is filed as Exhibit 5.1

The filing

CompanyCalciMedica, Inc. (CALC)
Form8-K, current report
Filed with the SECSep 30, 2026, 4:07 PM ET
Accession number0001193125-26-409049

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.